Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia
NCT04348448 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 100
Last updated 2023-07-21
Summary
The study is configured as a retrospective and prospective observational study. The study will be multi-center and will involve all COVID-19 pneumonia patients treated with canakinumab administered subcutaneously.
Conditions
Interventions
- DRUG
-
Canakinumab 150 MG/ML [Ilaris]
COVID-19
Sponsors & Collaborators
-
AUSL Romagna Rimini
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-02-01
- Primary Completion
- 2020-05-01
- Completion
- 2020-09-01
Countries
- Italy
Study Locations
More Related Trials
-
The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency
NCT02020434 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Neutrexin Plus Leucovorin in the Treatment of Pneumocystis Carinii Pneumonia (PCP)
NCT00002434 ·Status: COMPLETED ·Phase: NA
-
Safety, Tolerability and Efficacy of Uproleselan (GMI-1271) in Patients With COVID-19 Pneumonia
NCT05057221 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271
NCT02724085 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics of KBPA-101 in Hospital Acquired Pneumonia Caused by O11 Pseudomonas Aeruginosa
NCT00851435 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Octanorm Subcutaneous IG in Patients With PID
NCT01888484 ·Status: COMPLETED ·Phase: PHASE3
-
Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.
NCT04878055 ·Status: COMPLETED ·Phase: PHASE3
-
A Double-Blind Study To Evaluate the Long-Term Safety and Effectiveness of 60 mg Versus 120 mg of Aerosol Pentamidine in the Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients
NCT00002054 ·Status: COMPLETED ·Phase: NA
-
Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration -
NCT01793688 ·Status: COMPLETED
-
Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia
NCT03027609 ·Status: COMPLETED ·Phase: PHASE2
-
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
NCT05254990 ·Status: TERMINATED ·Phase: PHASE3
-
Ertapenem Administered Subcutaneously Versus Intravenously
NCT03218800 ·Status: TERMINATED ·Phase: PHASE3
-
An Open-label, Randomized, Parallel-arm Study Investigating the Efficacy and Safety of Intravenous Administration of Pamrevlumab Versus Standard of Care in Patients With COVID-19
NCT05262309 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)
NCT05204563 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)
NCT06766825 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease
NCT06499233 ·Status: RECRUITING ·Phase: PHASE4
-
Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia
NCT00640926 ·Status: COMPLETED ·Phase: PHASE2
-
Low Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Jirovecii Pneumonia
NCT04851015 ·Status: RECRUITING ·Phase: PHASE3
-
Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.
NCT02940626 ·Status: TERMINATED ·Phase: PHASE2
-
An Open-label, Randomized, and Comparative Study to Evaluate the Efficacy and Safety of Cefoperazone/Sulbactam in Comparison to Cefepime for the Treatment of Hospital-acquired Pneumonia and Healthcare-associated Pneumonia
NCT01280461 ·Status: UNKNOWN
-
PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB
NCT05685615 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections
NCT00965848 ·Status: COMPLETED ·Phase: PHASE4
-
11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
NCT03424525 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
NCT02452047 ·Status: COMPLETED ·Phase: PHASE3
-
TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients
NCT04716556 ·Status: COMPLETED ·Phase: NA